Food and Medicine Homologous Plants in Osteoporosis: A Scoping Review of Preclinical Evidence
Abstract
Osteoporosis is a chronic systemic bone disease characterized by reduced bone density and an increased risk of fractures. This review summarizes the preclinical evidence for 61 FMH plants and their active ingredients. Its bone protection mechanism involves estrogen-like action, inhibition of oxidative stress, regulation of intestinal flora and metabolites, regulation of autophagy, and other pathways. Based on a tertiary level of evidence, 24 plants had only a single animal/in vitro study (level 1), 34 had consistent results from multiple independent animal studies (level 2), and a few had preliminary human trials with obvious limitations (level 3). The existing evidence does not support FMH to replace standard anti-osteoporotic drugs and should be positioned as an adjunctive strategy for long-term prevention and early intervention, with standardized extracts and clinical trials with fractures as the endpoint in the future.
Read the paper
Related studies
- Irisin Enhances Osteoblast DifferentiationIn Vitro
- Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo
- Interaction between Schwann Cells and Osteoblasts In Vitro
- Administration of cinnamaldehyde promotes osteogenesis in ovariectomized rats and differentiation of osteoblast in vitro
- The Effect of the Major Components of Fructus Cnidii on Osteoblasts In Vitro
- Estrogen depletion alters osteogenic differentiation and matrix production by osteoblasts in vitro
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.